Illumina adds 2 medtech execs to its board

Illumina adds 2 medtech execs to its board, weakening Icahn's ...

The election of MacMillan and Ullem, two veteran leaders of publicly traded medtech companies, expands Illumina's board to 11 from nine members.

Illumina's Board of Directors elects two experienced Independent ...

The first, Stephen P. MacMillan, Chairman, President and Chief Executive Officer of Hologic, a medical device and diagnostic manufacturer, will ...

Illumina gets two new executives as the San Diego biotech revamps ...

Ankur Dhingra will take over as Illumina's new chief financial officer starting April 15, the company announced Tuesday.

Illumina Ventures Adds Two New Experts as Advisors

Illumina Ventures, a leading genomics and precision health venture firm, today announced that Timothy Stenzel, MD, PhD, and Jerry Steiner have joined the team ...

Illumina shakes up executive team, lowers 2023 outlook

... the departure of its ... Recommended Reading. Illumina adds 2 medtech execs to its board, weakening Icahn's influence By Susan Kelly • June 2, ...

Illumina Taps Hologic, Edwards Execs for Board

Illumina has elected two independent board members to join its board immediately. Stephen MacMillan, chairman, president, and CEO of Hologic ...

Illumina expands board after fight with Icahn | Reuters

Illumina Inc on Friday said it had expanded its board, adding two C-suite executives a week after shareholders voted to replace the gene ...

Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob ...

He will stay on in an advisory role through June 30 to support two new executive management team appointments. ... the genome," said Jacob Thaysen ...

Hologic CEO MacMillan to chair Illumina's board - MassDevice

Illumina (NASDAQ: ILMN) announced today that its board has elected Hologic CEO Stephen MacMillan to fill a new seat and become its non-executive chair.

Illumina's Board of Directors elects two experienced Independent ...

... an independent director and non-executive Chair of Illumina's board. The second, Scott B. Ullem, Corporate Vice President and Chief ...

Illumina Announces Board Changes

The entire Illumina team wishes Jay all the best as he embarks on his new chapter,” said Francis deSouza, Chief Executive Officer. “John's extensive leadership ...

StockWatch: Investors, Analysts Debate Background of New Illumina ...

As a result of the first two risks, Dickinson continued, Illumina will need to rely on its new board chair, Stephen P. MacMillan, who ...

Chutes & Ladders—Illumina names new CEO after a stormy summer

Grogan was one of two executives to depart as part of the restructuring. ... his post, alongside his spot as chair of the board, on Sept.

Illumina Names Jacob Thaysen as New CEO - WSJ

San Diego-based Illumina said Thaysen will become a member of its board upon joining the company. Charles Dadswell, Illumina's interim CEO ...

Illumina Management Team

At Illumina, our core values stem from innovation, discovery, and collaboration. As an executive team, we strive to deliver leading genomic technologies that ...

The Top 25 Medical Device Executives of 2024

Bergman has been Chairman of the Board and Chief Executive Officer of Henry Schein, Inc., a Fortune 500® company that provides healthcare ...

Illumina shareholders vote in one Carl Icahn nominee over chairman

The activist investor suggested that his associates replace Illumina CEO Francis deSouza, current board ... adding that it's “[looking] ...

Illumina CFO steps down amid executive shakeup - Yahoo Finance

... the Grail separation, the analysts added. In step two, Evercore expects the CEO to focus on turning around Illumina's core business.

Illumina in the News | What others say about us and our technology

Illumina gets two new executives as the San Diego biotech revamps its C-suite. Apr 9, 2024, GEN News, Best of NGS: The Instrument Companies to Watch. Apr 3 ...

Illumina Appoints New CEO | The Healthcare Technology Report.

... the appointment of Icahn's nominee, Andrew Teno, to the board. ... Two Big-Hit Breast Cancer Drug Trials Add to AstraZeneca's Streak.